|
1.
|
A JemalR SiegelE WardY HaoJ XuT MurrayMJ
ThunCancer statistics, 2008CA Cancer J
Clin587196200810.3322/CA.2007.0010
|
|
2.
|
M TarawnehO NimriK ArkoobM Al ZhagalCancer
Incidence in Jordan annual report, 2009
|
|
3.
|
C PennaB NordlingerColorectal metastasis
(liver and lung)Surg Clin North
Am8210751090200210.1016/S0039-6109(02)00051-812507210
|
|
4.
|
JH Van KriekenA JungT KirchnerKRAS
mutation testing for predicting response to anti-EGFR therapy for
colorectal carcinoma: proposal for an European quality assurance
programVirchows Arch453417431200818802721
|
|
5.
|
K FransėnM KlintenäsA OsterströmMutation
analysis of the BRAF, ARAF and RAF-1 genes in human colorectal
adenocarcinomasCarcinogenesis25527533200414688025
|
|
6.
|
DJ JonkerCJ O’CallaghanCS
KarapetisCetuximab for the treatment of colorectal cancerN Engl J
Med35720402048200710.1056/NEJMoa07183418003960
|
|
7.
|
E Van CutsemS SienaY HumbletAn open-label,
single-arm study assessing safety and efficacy of panitumumab in
patients with metastatic colorectal cancer refractory to standard
chemotherapyAnn Oncol199298200817785764
|
|
8.
|
RG AmadoM WolfM PeetersE Van
CutsemWild-type KRAS is required for panitumumab efficacy in
patients with metastatic colorectal cancerJ Clin
Oncol2616261634200810.1200/JCO.2007.14.711618316791
|
|
9.
|
S Khambata-FordCR GarrettNJ
MeropolExpression of epiregulin and amphiregulin and K-ras mutation
status predict disease control in metastatic colorectal cancer
patients treated with cetuximabJ Clin
Oncol2532303237200710.1200/JCO.2006.10.543717664471
|
|
10.
|
CS KarapetisS Khambata-FordDJ JonkerK-ras
mutations and benefit from cetuximab in advanced colorectal cancerN
Engl J Med35917571765200810.1056/NEJMoa080438518946061
|
|
11.
|
M ZenkerK LehmannAL SchulzExpansion of the
genotypic and phenotypic spectrum in patients with KRAS germline
mutationsJ Med Genet44131135200710.1136/jmg.2006.04630017056636
|
|
12.
|
R WongD CunninghamUsing predictive
biomarkers to select patients with advanced colorectal cancer for
treatment with epidermal growth factor receptor antibodiesJ Clin
Oncol2656685670200810.1200/JCO.2008.19.502419001346
|
|
13.
|
T MinamotoM MaiZ RonaiK-ras mutation:
early detection in molecular diagnosis and risk assessment of
colorectal, pancreas, and lung cancers - a reviewCancer Detect
Prev24112200010757118
|
|
14.
|
D CalistriC RengucciI SeymourMutation
analysis of p53, K-ras, and BRAF genes in colorectal cancer
progressionJ Cell Physiol204484488200510.1002/jcp.2031015702478
|
|
15.
|
A LièvreJB BachetD Le CorreKRAS mutation
status is predictive of response to cetuximab therapy in colorectal
cancerCancer Res6639923995200616618717
|
|
16.
|
S EdkinsS O’MearaA ParkerRecurrent KRAS
codon 146 mutations in human colorectal cancerCancer Biol
Ther5928932200610.4161/cbt.5.8.325116969076
|
|
17.
|
P CejasM López-GómezC AguayoKRAS mutations
in primary colorectal cancer tumors and related metastases: a
potential role in prediction of lung metastasisPLoS
One4e8199200910.1371/journal.pone.000819920020061
|
|
18.
|
CG FerreiraI Zalcberg-RenaultFM VieiraMH
BonaminoM ZalisAnalysis of KRAS mutations in colorectal cancer
(CRC) patients by gender in a Brazilian cohort of 3,346 patientsJ
Clin Oncol2815s2010
|
|
19.
|
J AbubakerP BaviW Al-HaqawiPrognostic
significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS
mutations in colorectal carcinomaJ
Pathol219435445200910.1002/path.262519824059
|
|
20.
|
M ConzelmannU LinnemannMR BergerK-ras
codon 12 and 13 mutations are correlated with differential patterns
of tumor cell dissemination in colorectal cancer patientsInt J
Oncol2415371544200415138598
|
|
21.
|
A LicarP CerkovnikJ OcvirkS NovakovicKRAS
mutations in Slovene patients with colorectal cancer: frequency,
distribution and correlation with the response to treatmentInt J
Oncol3611371144201020372787
|
|
22.
|
ER FearonMolecular genetic studies of the
adenoma-carcinoma sequenceAdv Intern Med3912314719948140953
|
|
23.
|
P ShawS TardyE BenitoOccurrence of Ki-ras
and p53 mutations in primary colorectal
tumorsOncogene62121212819911945416
|
|
24.
|
M Herreros-VillanuevaG AggarwalKRAS assay
selection: sensitivity and accuracy in clinical applicationMol Biol
Rep3924672470201210.1007/s11033-011-0997-621656377
|
|
25.
|
P PintoP RochaI VeigaComparison of
methodologies for KRAS mutation detection in metastatic colorectal
cancerCancer
Genet20443946201110.1016/j.cancergen.2011.07.00321962894
|
|
26.
|
AS SolimanML BondySA El-BadawyContrasting
molecular pathology of colorectal carcinoma in Egyptian and Western
patientsBr J Cancer8510371046200110.1054/bjoc.2001.183811592777
|
|
27.
|
T NagasakaH SasamotoK NotoharaColorectal
cancer with mutation in BRAF, KRAS, and wild-type with respect to
both oncogenes showing different patterns of DNA methylationJ Clin
Oncol2245844594200410.1200/JCO.2004.02.15415542810
|
|
28.
|
N SharmaM SaifoI TamaskarR BhuvaneswariT
MashtareM FakihKRAS status and clinical outcome in metastatic
colorectal cancer patients treated with first-line FOLFOX
chemotherapyJ Gastrointest Oncol19096201022811812
|
|
29.
|
HJ AndreyevAR NormanD CunninghamKirsten
ras mutations in patients with colorectal cancer: the ‘RASCAL II’
studyBr J Cancer856926962001
|
|
30.
|
D SantiniF LoupakisB VincenziHigh
concordance of KRAS status between primary colorectal tumors and
related metastatic sites: implications for clinical
practiceOncologist1312701275200810.1634/theoncologist.2008-018119056857
|
|
31.
|
MC Etienne-GrimaldiJL FormentoM
FrancoualK-Ras mutations and treatment outcome in colorectal cancer
patients receiving exclusive fluoropyrimidine therapyClin Cancer
Res1448304835200810.1158/1078-0432.CCR-07-4906
|
|
32.
|
S ArtaleA Sartore-BianchiSM
VeroneseMutations of KRAS and BRAF in primary and matched
metastatic sites of colorectal cancerJ Clin
Oncol2642174219200810.1200/JCO.2008.18.728618757341
|
|
33.
|
B VogelsteinER FearonSR HamiltonGenetic
alterations during colorectal-tumor developmentN Engl J
Med319525532198810.1056/NEJM1988090131909012841597
|
